▲ +117.01% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for FibroGen in the last 3 months. The average price target is $45.83, with a high forecast of $58.00 and a low forecast of $29.00. The average price target represents a 117.01% upside from the last price of $21.12.
The current consensus among 8 polled investment analysts is to hold stock in FibroGen. This rating has held steady since October 2020, when it changed from a Buy consensus rating.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.